A novel treatment to enhance survival for end stage triple negative breast cancer using repurposed veterinary anthelmintics combined with gut‑supporting/immune enhancing molecules

Iragavarapu‑Charyulu,Vijaya; Shakya,Rojesh; Robinson,Philip; Guzmán,Esther; Tyulmenkova,Anastasia; Pino,Jose Labrador; Isgor,Ceylan

doi:10.3892/or.2023.8690

A novel treatment to enhance survival for end stage triple negative breast cancer using repurposed veterinary anthelmintics combined with gut‑supporting/immune enhancing molecules

Authors:
- Vijaya Iragavarapu‑Charyulu
- Rojesh Shakya
- Philip Robinson
- Esther Guzmán
- Anastasia Tyulmenkova
- Jose Labrador Pino
- Ceylan Isgor
View Affiliations

Affiliations: Department of Basic Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431‑0991, USA, Department of Clinical Sciences, Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL 33431‑0991, USA, Harbor Branch Oceanographic Institute at Florida Atlantic University, 5600 US 1 North, Fort Pierce, FL 34946‑7331, USA
Published online on: December 22, 2023 https://doi.org/10.3892/or.2023.8690
Article Number: 31

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Patients with end‑stage metastatic disease have limited treatment options and those diagnosed with triple negative breast cancer (Her2, Estrogen receptor, Progesterone receptor) have a poor prognosis. Using a triple negative mammary tumor model selected for brain metastasis (4T1Br4) in the mouse, treatment options that may increase survival when therapeutics are applied at post‑metastasis were assessed. Anti‑parasitic benzimidazoles (BZs) destabilize microtubules, inhibit metabolic pathways, reduce cell proliferation, and induce apoptosis in tumor cells. Co‑administration of two BZs was selected, oxfendazole (OFZ) and parbendazole (PBZ), shown to overcome resistance development in anthelmintic effects by imposing metabolic delay to assess if multiple BZ approach is also suitable to enhance anticancer effects. It has been previously reported that treatment of mammary tumor‑bearing mice at an early stage with chitin microparticles (CMPs) decreased tumor growth and metastases by enhancing both innate M1 macrophage and TH1 adaptive immune response. Oral administration of CMPs was previously revealed to affect the gut in intestinal inflammation. A combination BZ (OFZ/PBZ) and CMP treatment was tested to target tumor development and metastasis and effects were compared in response to monotherapies of the same compounds or to untreated mice. The results demonstrated increased survival, decreased tumor cell proliferation, decreased metastasis in lungs and brain, increased levels of fecal SCFAs butyric, acetic, propionic and valeric acids with increased butyric and propionic acid levels in brain biopsies in combination treated compared with untreated mice. At the primary tumor, SCFA receptor FFAR2 expression was increased in combination treatment compared with untreated mice, suggestive of a non‑invasive cancer phenotype. The superior cytotoxic effects of OFZ/PBZ were confirmed as opposed to single treatment with OFZ or PBZ using 3D spheroids generated from a human breast cancer cell line, MDA‑MB‑468. These data are compelling for treatment option possibility even at late stages of metastasized breast cancer.

View References

1	Bou Zerdan M, Ghorayeb T, Saliba F, Allam S, Bou Zerdan M, Yaghi M, Bilani N, Jaafar R and Nahleh Z: Triple negative breast cancer: Updates on classification and treatment in 2021. Cancers (Basel). 14:12532022. View Article : Google Scholar : PubMed/NCBI
2	Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, O'Regan R, Torres MA and Meisel JL: Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer. Breast Cancer Res Treat. 161:279–287. 2017. View Article : Google Scholar : PubMed/NCBI
3	Jhan JR and Andrechek ER: Triple-negative breast cancer and the potential for targeted therapy. Pharmacogenomics. 18:1595–1609. 2017. View Article : Google Scholar : PubMed/NCBI
4	Tutt ANJ, Garber JE and Geyer CE Jr: Adjuvant olaparib in BRCA-mutated breast cancer. Reply. N Engl J Med. 385:14402021.PubMed/NCBI
5	Yin J, Zhou C, Wang G and Gu J: Treatment for triple-negative breast cancer: An umbrella review of meta-analyses. Int J Gen Med. 15:5901–5914. 2022. View Article : Google Scholar : PubMed/NCBI
6	Zagami P and Carey LA: Triple negative breast cancer: Pitfalls and progress. NPJ Breast Cancer. 8:952022. View Article : Google Scholar : PubMed/NCBI
7	Baranova A, Krasnoselskyi M, Starikov V, Kartashov S, Zhulkevych I, Vlasenko V, Oleshko K, Bilodid O, Sadchikova M and Vinnyk Y: Triple-negative breast cancer: Current treatment strategies and factors of negative prognosis. J Med Life. 15:153–161. 2022. View Article : Google Scholar : PubMed/NCBI
8	Pedersen RN, Esen BÖ, Mellemkjær L, Christiansen P, Ejlertsen B, Lash TL, Nørgaard M and Cronin-Fenton D: The incidence of breast cancer recurrence 10–32 years after primary diagnosis. J Natl Cancer Inst. 114:391–399. 2022. View Article : Google Scholar : PubMed/NCBI
9	Landry I, Sumbly V and Vest M: Advancements in the treatment of triple-negative breast cancer: A narrative review of the literature. Cureus. 14:e219702022.PubMed/NCBI
10	Buchta Rosean C, Bostic RR, Ferey JCM, Feng TY, Azar FN, Tung KS, Dozmorov MG, Smirnova E, Bos PD and Rutkowski MR: Preexisting commensal dysbiosis is a host-intrinsic regulator of tissue inflammation and tumor cell dissemination in hormone receptor-positive breast cancer. Cancer Res. 79:3662–3675. 2019. View Article : Google Scholar : PubMed/NCBI
11	Kim CH: Control of lymphocyte functions by gut microbiota-derived short-chain fatty acids. Cell Mol Immunol. 18:1161–1171. 2021. View Article : Google Scholar : PubMed/NCBI
12	Rossi T, Vergara D, Fanini F, Maffia M, Bravaccini S and Pirini F: Microbiota-derived metabolites in tumor progression and metastasis. Int J Mol Sci. 21:57862020. View Article : Google Scholar : PubMed/NCBI
13	Thirunavukkarasan M, Wang C, Rao A, Hind T, Teo YR, Siddiquee AA, Goghari MAI, Kumar AP and Herr DR: Short-chain fatty acid receptors inhibit invasive phenotypes in breast cancer cells. PLoS One. 12:e01863342017. View Article : Google Scholar : PubMed/NCBI
14	Son DS, Lee ES and Adunyah SE: The antitumor potentials of benzimidazole anthelmintics as repurposing drugs. Immune Netw. 20:e292020. View Article : Google Scholar : PubMed/NCBI
15	Bai RY, Staedtke V, Wanjiku T, Rudek MA, Joshi A, Gallia GL and Riggins GJ: Brain penetration and efficacy of different mebendazole polymorphs in a mouse brain tumor model. Clin Cancer Res. 21:3462–3470. 2015. View Article : Google Scholar : PubMed/NCBI
16	De Witt M, Gamble A, Hanson D, Markowitz D, Powell C, Al Dimassi S, Atlas M, Boockvar J, Ruggieri R and Symons M: Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors. Mol Med. 23:50–56. 2017. View Article : Google Scholar : PubMed/NCBI
17	Bai RY, Staedtke V, Aprhys CM, Gallia GL and Riggins GJ: Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol. 13:974–982. 2011. View Article : Google Scholar : PubMed/NCBI
18	Zhang L, Bochkur Dratver M, Yazal T, Dong K, Nguyen A, Yu G, Dao A, Bochkur Dratver M, Duhachek-Muggy S, Bhat K, et al: Mebendazole potentiates radiation therapy in triple-negative breast cancer. Int J Radiat Oncol Biol Phys. 103:195–207. 2019. View Article : Google Scholar : PubMed/NCBI
19	Gao P, Dang CV and Watson J: Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins. J Am Assoc Lab Anim Sci. 47:37–40. 2008.PubMed/NCBI
20	Choi HS, Ko YS, Jin H, Kang KM, Ha IB, Jeong H, Song HN, Kim HJ and Jeong BK: Anticancer effect of benzimidazole derivatives, especially mebendazole, on triple-negative breast cancer (TNBC) and radiotherapy-resistant TNBC in vivo and in vitro. Molecules. 26:51182021. View Article : Google Scholar : PubMed/NCBI
21	Laudisi F, Marônek M, Di Grazia A, Monteleone G and Stolfi C: Repositioning of anthelmintic drugs for the treatment of cancers of the digestive system. Int J Mol Sci. 21:49572020. View Article : Google Scholar : PubMed/NCBI
22	Hori A, Imaeda Y, Kubo K and Kusaka M: Novel benzimidazole derivatives selectively inhibit endothelial cell growth and suppress angiogenesis in vitro and in vivo. Cancer Lett. 183:53–60. 2002. View Article : Google Scholar : PubMed/NCBI
23	Mrkvová Z, Uldrijan S, Pombinho A, Bartůněk P and Slaninová I: Benzimidazoles downregulate Mdm2 and MdmX and activate p53 in MdmX overexpressing tumor cells. Molecules. 24:21522019. View Article : Google Scholar : PubMed/NCBI
24	Zhang D and Kanakkanthara A: Beyond the paclitaxel and vinca alkaloids: Next generation of plant-derived microtubule-targeting agents with potential anticancer activity. Cancers (Basel). 12:17212020. View Article : Google Scholar : PubMed/NCBI
25	Falzone L, Bordonaro R and Libra M: SnapShot: Cancer chemotherapy. Cell. 186:1816–1816.e1. 2023. View Article : Google Scholar
26	McGrogan BT, Gilmartin B, Carney DN and McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 1785:96–132. 2008.PubMed/NCBI
27	Dhyani P, Quispe C, Sharma E, Bahukhandi A, Sati P, Attri DC, Szopa A, Sharifi-Rad J, Docea AO, Mardare I, et al: Anticancer potential of alkaloids: A key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine. Cancer Cell Int. 22:2062022. View Article : Google Scholar : PubMed/NCBI
28	Singh R, Bal MS, Singla LD and Kaur P: Detection of anthelmintic resistance in sheep and goat against fenbendazole by faecal egg count reduction test. J Parasit Dis. 41:463–466. 2017. View Article : Google Scholar : PubMed/NCBI
29	Hennessy DR, Steel JW, Prichard RK and Lacey E: The effect of co-administration of parbendazole on the disposition of oxfendazole in sheep. J Vet Pharmacol Ther. 15:10–18. 1992. View Article : Google Scholar : PubMed/NCBI
30	Hennessy DR, Lacey E, Prichard RK and Steel JW: Potentiation of the anthelmintic activity of oxfendazole by parbendazole. J Vet Pharmacol Ther. 8:270–275. 1985. View Article : Google Scholar : PubMed/NCBI
31	Gonzalez AE, Codd EE, Horton J, Garcia HH and Gilman RH: Oxfendazole: A promising agent for the treatment and control of helminth infections in humans. Expert Rev Anti Infect Ther. 17:51–56. 2019. View Article : Google Scholar : PubMed/NCBI
32	Xu D, Tian W, Jiang C, Huang Z and Zheng S: The anthelmintic agent oxfendazole inhibits cell growth in non-small cell lung cancer by suppressing c-Src activation. Mol Med Rep. 19:2921–2926. 2019.PubMed/NCBI
33	Florio R, Veschi S, Di Giacomo V, Pagotto S, Carradori S, Verginelli F, Cirilli R, Casulli A, Grassadonia A, Tinari N, et al: The benzimidazole-based anthelmintic parbendazole: A repurposed drug candidate that synergizes with gemcitabine in pancreatic cancer. Cancers (Basel). 11:20422019. View Article : Google Scholar : PubMed/NCBI
34	Libreros S, Garcia-Areas R, Keating P, Gazaniga N, Robinson P, Humbles A and Iragavarapu-Charyulu VL: Allergen induced pulmonary inflammation enhances mammary tumor growth and metastasis: Role of CHI3L1. J Leukoc Biol. 97:929–940. 2015. View Article : Google Scholar : PubMed/NCBI
35	Cai Y, Zhou J and Webb DC: Treatment of mice with fenbendazole attenuates allergic airways inflammation and Th2 cytokine production in a model of asthma. Immunol Cell Biol. 87:623–629. 2009. View Article : Google Scholar : PubMed/NCBI
36	Goff SL and Danforth DN: The role of immune cells in breast tissue and immunotherapy for the treatment of breast cancer. Clin Breast Cancer. 21:e63–e73. 2021. View Article : Google Scholar : PubMed/NCBI
37	Libreros S, Garcia-Areas R and Iragavarapu-Charyulu V: CHI3L1 plays a role in cancer through enhanced production of pro-inflammatory/pro-tumorigenic and angiogenic factors. Immunol Res. 57:99–105. 2013. View Article : Google Scholar : PubMed/NCBI
38	Kim SH, Redvers RP, Chi LH, Ling X, Lucke AJ, Reid RC, Fairlie DP, Martin ACBM, Anderson RL, Denoyer D and Pouliot N: Identification of brain metastasis genes and therapeutic evaluation of histone deacetylase inhibitors in a clinically relevant model of breast cancer brain metastasis. Dis Model Mech. 11:DMM0348502018. View Article : Google Scholar : PubMed/NCBI
39	Holliday DL and Speirs V: Choosing the right cell line for breast cancer research. Breast Cancer Res. 13:2152011. View Article : Google Scholar : PubMed/NCBI
40	Kim JB, Urban K, Cochran E, Lee S, Ang A, Rice B, Bata A, Campbell K, Coffee R, Gorodinsky A, et al: Non-invasive detection of a small number of bioluminescent cancer cells in vivo. PLoS One. 5:e93642010. View Article : Google Scholar : PubMed/NCBI
41	Erny D, Hrabě de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, Keren-Shaul H, Mahlakoiv T, Jakobshagen K, Buch T, et al: Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 18:965–977. 2015. View Article : Google Scholar : PubMed/NCBI
42	Strong P, Clark H and Reid K: Intranasal application of chitin microparticles down-regulates symptoms of allergic hypersensitivity to Dermatophagoides pteronyssinus and Aspergillus fumigatus in murine models of allergy. Clin Exp Allergy. 32:1794–1800. 2002. View Article : Google Scholar : PubMed/NCBI
43	Nishiyama A, Tsuji S, Yamashita M, Henriksen RA, Myrvik QN and Shibata Y: Phagocytosis of N-acetyl-D-glucosamine particles, a Th1 adjuvant, by RAW 264.7 cells results in MAPK activation and TNF-alpha, but not IL-10, production. Cell Immunol. 239:103–112. 2006. View Article : Google Scholar : PubMed/NCBI
44	Workman P, Balmain A, Hickman JA, McNally NJ, Rohas AM, Mitchison NA, Pierrepoint CG, Raymond R, Rowlatt C, Stephens TC, et al: UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab Anim. 22:195–201. 1988. View Article : Google Scholar : PubMed/NCBI
45	Montgomery C: Oncologic and toxicologic research: Alleviation and control of pain and distress in laboratory animals. Cancer Bull. 42:230–237. 1990.
46	Ullman-Culleré MH and Foltz CJ: Body condition scoring: A rapid and accurate method for assessing health status in mice. Lab Anim Sci. 49:319–323. 1999.PubMed/NCBI
47	Isgor C and Watson SJ: Estrogen receptor alpha and beta mRNA expressions by proliferating and differentiating cells in the adult rat dentate gyrus and subventricular zone. Neuroscience. 134:847–856. 2005. View Article : Google Scholar : PubMed/NCBI
48	Shihan MH, Novo SG, Le Marchand SJ, Wang Y and Duncan MK: A simple method for quantitating confocal fluorescent images. Biochem Biophys Rep. 25:1009162021.PubMed/NCBI
49	Han J, Lin K, Sequeira C and Borchers CH: An isotope-labeled chemical derivatization method for the quantitation of short-chain fatty acids in human feces by liquid chromatography-tandem mass spectrometry. Anal Chim Acta. 854:86–94. 2015. View Article : Google Scholar : PubMed/NCBI
50	Saha S, Day-Walsh P, Shehata E and Kroon PA: Development and validation of a LC-MS/MS technique for the analysis of short chain fatty acids in tissues and biological fluids without derivatisation using isotope labelled internal standards. Molecules 26: 6444, 2021. https://doi.org/10.3390/molecules26216444
51	Nagatomo R, Kaneko H, Kamatsuki S, Ichimura-Shimizu M, Ishimaru N, Tsuneyama K and Inoue K: Short-chain fatty acids profiling in biological samples from a mouse model of Sjögren's syndrome based on derivatized LC-MS/MS assay. J Chromatogr B Analyt Technol Biomed Life Sci. 1210:1234322022. View Article : Google Scholar : PubMed/NCBI
52	Guzmán EA, Pitts TP, Winder PL and Wright AE: The marine natural product furospinulosin 1 induces apoptosis in MDA-MB-231 triple negative breast cancer cell spheroids, but not in cells grown traditionally with longer treatment. Mar Drugs. 19:2492021. View Article : Google Scholar : PubMed/NCBI
53	Das GC, Holiday D, Gallardo R and Haas C: Taxol-induced cell cycle arrest and apoptosis: Dose-response relationship in lung cancer cells of different wild-type p53 status and under isogenic condition. Cancer Lett. 165:147–153. 2001. View Article : Google Scholar : PubMed/NCBI
54	Mikhail AS, Eetezadi S and Allen C: Multicellular tumor spheroids for evaluation of cytotoxicity and tumor growth inhibitory effects of nanomedicines in vitro: A comparison of docetaxel-loaded block copolymer micelles and Taxotere^®. PLoS One. 8:e626302013. View Article : Google Scholar : PubMed/NCBI
55	Adcock AF, Trivedi G, Edmondson R, Spearman C and Yang L: Three-dimensional (3D) cell cultures in cell-based assays for in-vitro evaluation of anticancer drugs. J Anal Bioanal Tech. 6:2472015. View Article : Google Scholar
56	Sazonova EV, Kopeina GS, Imyanitov EN and Zhivotovsky B: Platinum drugs and taxanes: Can we overcome resistance? Cell Death Discov. 7:1552021. View Article : Google Scholar : PubMed/NCBI
57	Mann J, Yang N, Montpetit R, Kirschenman R, Lemieux H and Goping IS: BAD sensitizes breast cancer cells to docetaxel with increased mitotic arrest and necroptosis. Sci Rep. 10:3552020. View Article : Google Scholar : PubMed/NCBI
58	Wang TH, Wang HS and Soong YK: Paclitaxel-induced cell death: Where the cell cycle and apoptosis come together. Cancer. 88:2619–2628. 2000. View Article : Google Scholar : PubMed/NCBI
59	Yang G, Chen S, Deng B, Tan C, Deng J, Zhu G, Yin Y and Ren W: Implication of G protein-coupled receptor 43 in intestinal inflammation: A mini-review. Front Immunol. 9:14342018. View Article : Google Scholar : PubMed/NCBI
60	Spagnuolo PA, Hu J, Hurren R, Wang X, Gronda M, Sukhai MA, Di Meo A, Boss J, Ashali I, Beheshti Zavareh R, et al: The antihelmintic flubendazole inhibits microtubule function through a mechanism distinct from vinca alkaloids and displays preclinical activity in leukemia and myeloma. Blood. 115:4824–4833. 2010. View Article : Google Scholar : PubMed/NCBI
61	Furtado LFV, de Paiva Bello ACP and Rabelo ÉML: Benzimidazole resistance in helminths: From problem to diagnosis. Acta Trop. 162:95–102. 2016. View Article : Google Scholar : PubMed/NCBI
62	Moudi M, Go R, Yien CYS and Nazre M: Vinca alkaloids. Int J Prev Med. 4:1231–1235. 2013.PubMed/NCBI
63	Zhou J and Giannakakou P: Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents. 5:65–71. 2005. View Article : Google Scholar : PubMed/NCBI
64	Redman E, Whitelaw F, Tait A, Burgess C, Bartley Y, Skuce PJ, Jackson F and Gilleard JS: The emergence of resistance to the benzimidazole anthlemintics in parasitic nematodes of livestock is characterised by multiple independent hard and soft selective sweeps. PLoS Negl Trop Dis. 9:e00034942015. View Article : Google Scholar : PubMed/NCBI
65	Lv Y, Ma X, Du Y and Feng J: Understanding patterns of brain metastasis in triple-negative breast cancer and exploring potential therapeutic targets. Onco Targets Ther. 14:589–607. 2021. View Article : Google Scholar : PubMed/NCBI
66	Syriac AK, Nandu NS and Leone JP: Central nervous system metastases from triple-negative breast cancer: Current treatments and future prospective. Breast Cancer (Dove Med Press). 14:1–13. 2022.PubMed/NCBI
67	Dogra N, Kumar A and Mukhopadhyay T: Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Sci Rep. 8:119262018. View Article : Google Scholar : PubMed/NCBI
68	Mirzaei R, Afaghi A, Babakhani S, Sohrabi MR, Hosseini-Fard SR, Babolhavaeji K, Khani Ali Akbari S, Yousefimashouf R and Karampoor S: Role of microbiota-derived short-chain fatty acids in cancer development and prevention. Biomed Pharmacother. 139:1116192021. View Article : Google Scholar : PubMed/NCBI
69	Feitelson MA, Arzumanyan A, Medhat A and Spector I: Short-chain fatty acids in cancer pathogenesis. Cancer Metastasis Rev. 42:677–698. 2023. View Article : Google Scholar : PubMed/NCBI
70	Dutta J, Tripathi S and Dutta PK: Progress in antimicrobial activities of chitin, chitosan and its oligosaccharides: A systematic study needs for food applications. Food Sci Technol Int. 18:3–34. 2012. View Article : Google Scholar : PubMed/NCBI
71	Nagatani K, Wang S, Llado V, Lau CW, Li Z, Mizoguchi A, Nagler CR, Shibata Y, Reinecker HC, Mora JR and Mizoguchi E: Chitin microparticles for the control of intestinal inflammation. Inflamm Bowel Dis. 18:1698–1710. 2012. View Article : Google Scholar : PubMed/NCBI
72	Tedelind S, Westberg F, Kjerrulf M and Vidal A: Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: A study with relevance to inflammatory bowel disease. World J Gastroenterol. 13:2826–2832. 2007. View Article : Google Scholar : PubMed/NCBI
73	Liu Q, Tian X, Maruyama D, Arjomandi M and Prakash A: Lung immune tone via gut-lung axis: Gut-derived LPS and short-chain fatty acids' immunometabolic regulation of lung IL-1β, FFAR2 and FFAR3 expression. Am J Physiol Lung Cell Mol Physiol. 321:L65–L68. 2021. View Article : Google Scholar : PubMed/NCBI
74	Logsdon AF, Erickson MA, Rhea EM, Salameh TS and Banks WA: Gut reactions: How the blood-brain barrier connects the microbiome and the brain. Exp Biol Med (Maywood). 243:159–165. 2018. View Article : Google Scholar : PubMed/NCBI
75	Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W and Kunz-Schughart LA: Multicellular tumor spheroids: An underestimated tool is catching up again. J Biotechnol. 148:3–15. 2010. View Article : Google Scholar : PubMed/NCBI
76	Edmondson R, Broglie JJ, Adcock AF and Yang L: Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 12:207–218. 2014. View Article : Google Scholar : PubMed/NCBI
77	Riedl A, Schlederer M, Pudelko K, Stadler M, Walter S, Unterleuthner D, Unger C, Kramer N, Hengstschläger M, Kenner L, et al: Comparison of cancer cells in 2D vs 3D culture reveals differences in AKT-mTOR-S6K signaling and drug responses. J Cell Sci. 130:203–218. 2017.PubMed/NCBI
78	Rahimifard M, Bagheri Z, Hadjighassem M, Jaktaji RP, Behroodi E, Haghi-Aminjan H, Movahed MA, Latifi H, Hosseindoost S, Zarghi A and Pourahmad J: Investigation of anti-cancer effects of new pyrazino[1,2-a]benzimidazole derivatives on human glioblastoma cells through 2D in vitro model and 3D-printed microfluidic device. Life Sci. 302:1205052022. View Article : Google Scholar : PubMed/NCBI
79	Zhang X, Zhao J, Gao X, Pei D and Gao C: Anthelmintic drug albendazole arrests human gastric cancer cells at the mitotic phase and induces apoptosis. Exp Ther Med. 13:595–603. 2017. View Article : Google Scholar : PubMed/NCBI
80	Liu H, Sun H, Zhang B, Liu S, Deng S, Weng Z, Zuo B, Yang J and He Y: ¹⁸F-FDG PET imaging for monitoring the early anti-tumor effect of albendazole on triple-negative breast cancer. Breast Cancer. 27:372–380. 2020. View Article : Google Scholar : PubMed/NCBI
81	Dogra N and Mukhopadhyay T: Impairment of the ubiquitin-proteasome pathway by methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl)carbamate leads to a potent cytotoxic effect in tumor cells: A novel antiproliferative agent with a potential therapeutic implication. J Biol Chem. 287:30625–30640. 2012. View Article : Google Scholar : PubMed/NCBI
82	Pinto LC, Mesquita FP, Soares BM, da Silva EL, Puty B, de Oliveira EHC, Burbano RR and Montenegro RC: Mebendazole induces apoptosis via C-MYC inactivation in malignant ascites cell line (AGP01). Toxicol In Vitro. 60:305–312. 2019. View Article : Google Scholar : PubMed/NCBI
83	Chen Q, Li Y, Zhou X and Li R: Oxibendazole inhibits prostate cancer cell growth. Oncol Lett. 15:2218–2226. 2018.PubMed/NCBI
84	Zhou F, Du J and Wang J: Albendazole inhibits HIF-1α-dependent glycolysis and VEGF expression in non-small cell lung cancer cells. Mol Cell Biochem. 428:171–178. 2017. View Article : Google Scholar : PubMed/NCBI
85	Sung SJ, Kim HK, Hong YK and Joe YA: Autophagy is a potential target for enhancing the anti-angiogenic effect of mebendazole in endothelial cells. Biomol Ther (Seoul). 27:117–125. 2019. View Article : Google Scholar : PubMed/NCBI
86	Kralova V, Hanušová V, Caltová K, Špaček P, Hochmalová M, Skálová L and Rudolf E: Flubendazole and mebendazole impair migration and epithelial to mesenchymal transition in oral cell lines. Chem Biol Interact. 293:124–132. 2018. View Article : Google Scholar : PubMed/NCBI